RIO DE JANEIRO
December 18, 2012
/PRNewswire/ -- An advanced radiotherapy treatment system, fully equipped for treating cancer with advanced, image-guided radiotherapy and radiosurgery, has been ordered by Clínicas Oncológicas Integradas (GRUPO COI) for installation at the group's Botafogo site in
Rio de Janeiro
. The TrueBeam™ system, which was designed to treat tumors with great accuracy and speed, is the first to be ordered by a treatment center in
, and is slated to be installed by the end of 2013 pending final approvals by the relevant regulatory agencies in
"This system will enable us to treat cancer using high-quality radiotherapy and even radiosurgery procedures that are delivered more quickly and more precisely than is possible now," said Dr.
, Medical Vice President at GRUPO COI. "TrueBeam technology is especially suited for treating tumors that are close to or embedded in critical organs, such as cancers of the lung, liver, prostate, or spinal cord, where minimizing the exposure of surrounding healthy tissues is so important. With a TrueBeam system, we'll be able to use higher energy beams along with real-time image guidance for highly precise and targeted cancer treatments."
The TrueBeam system, which is made by Varian Medical Systems (NYSE:VAR), delivers powerful cancer treatments with pinpoint accuracy and precision. It integrates imaging and motion management technologies, making it possible to monitor and compensate for tumor motion during treatment.
Benefits of the System
"With this system, we'll be able to treat patients who wouldn't have other options," said Dr. Schaum. "For example, we are sometimes asked to use advanced modalities like IMRT and stereotactic radiosurgery to help patients who have relapsed after earlier courses of radiotherapy delivered using older technology. With the level of precision that TrueBeam affords, we can consider performing re-irradiations in some of these cases, because the technology will help us do a better job of minimizing the impact on surrounding healthy tissues that already received some dose and may be approaching their maximum tolerance."